Clinical trials: Autoimmunity, active
Type 1 Diabetes, Children
Think-Find-Solve Activities for Insulin Self-Management in Type 1 Diabetes
Children with type 1 diabetes require lifelong insulin therapy. However, improper management of insulin therapy may lead to serious, potentially life-threatening complications.
- Conditions
- Type 1 Diabetes, Children, Activity, Insulin
- Trial name
- NCT07670572
- Testing
- Insulin Self-Management Know-Find-Solve Activity Book, Routine education
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential…
- Trial name
- SMART-JIA (NCT06654882)
- Testing
- TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 400 people
- Sponsor
- Duke University
Multiple Sclerosis
Blood Flow Restriction for Upper Limb Rehabilitation in People With Multiple Sclerosis. A Randomized Controlled Trial (BFRT-EM)
Although the Blood Flow Restriction Training (BFRT) system has attracted the attention of health professionals, research on this tool in people with neurological pathology, particularly multiple sclerosis (MS), is very limited.
- Trial name
- BFRT-EM (NCT06795230)
- Testing
- Muscle strengthening (BFRT), Conventional physical therapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Universidad Rey Juan Carlos
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single…
- Trial name
- NCT07328581
- Testing
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Systemic Lupus Erythematosus (SLE)
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE).
- Trial name
- EMERALD (NCT05352919)
- Testing
- Litifilimab
- Where
- 214 sites in United States, Argentina and 26 more
- Volunteers
- 864 people
- Sponsor
- Biogen
Lupus Nephritis
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis
This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult (18-75 years) subjects with active LN suitable for systemic therapy.
- Trial name
- NCT07393451
- Testing
- SIM0278 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Birdshot Chorioretinopathy, Posterior Uveitis
Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)
The purpose of this study is twofold: 1. To analyze the clinical features of a cohort of patients with birdshot chorioretinopathy (BCR), an inflammatory bilateral ocular disease, affecting the choroid and the retina.
- Trial name
- CO-BIRD (NCT05153057)
- Testing
- Observational study
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 1 Diabetes, Closed Loop
Semi-closed Loop Automated Insulin Therapy in the Pediatric Population Aged 2-6 Years With Type 1 Diabetes: Impact on Quality of Life and Glycemic Control
The incidence of type 1 diabetes is increasing, with an incidence of +4% per year in France today. The treatment for type 1 diabetes is insulin therapy.
- Conditions
- Type 1 Diabetes, Closed Loop, Insulin, Quality of Life
- Trial name
- Diablife (NCT06875167)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Fondation Lenval
Rheumatoid Arthritis
Prospective Cohort Study on Refractory Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic erosive arthritis. Without timely and appropriate treatment, it can lead to joint destruction and disability.
- Trial name
- NCT07126431
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Third Hospital
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Rheumatoid Arthritis
Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)
The goal of this clinical trial is to compare therapeutic drug monitoring (TDM) versus Standard of care in patients with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor (adalimumab).
- Trial name
- RA-DRUM (NCT06440629)
- Testing
- Therapeutic drug monitoring (TDM) of adalimumab
- Where
- 22 sites in Austria, Italy and 4 more
- Volunteers
- 387 people
- Sponsor
- Diakonhjemmet Hospital
Lupus Nephritis, Systemic Lupus Erythematosus
US Zamto-cel Autoimmune Diseases
AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard…
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
- Trial name
- NCT06708845
- Testing
- zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Miltenyi Biomedicine GmbH
Type 1 Diabetes Mellitus, Stage 2 Type 1 Diabetes
Information, Follow-up and Early Diagnosis of Children at Risk for Type 1 Diabetes
The aim is to investigate whether screening for islet autoantibodies, regular follow-up, and increased knowledge in families about the progression of the disease in children at high genetic risk or with single or multiple islet…
- Conditions
- Type 1 Diabetes Mellitus, Stage 2 Type 1 Diabetes, Stage 1 Type 1 Diabetes, Stage 3 Type 1 Diabetes
- Trial name
- iT1D (NCT06676566)
- Where
- Sweden
- Volunteers
- 600 people
- Sponsor
- Lund University
Rheumatoid Arthritis
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting small joints, with a global prevalence of 0.5%-1.0% and 0.42% in China (around 5 million patients, mostly female and over 55).
- Trial name
- NCT07452445
- Testing
- Ivarmacitinib
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread…
- Trial name
- NCT07719322
- Where
- Egypt
- Volunteers
- 156 people
- Sponsor
- Assiut University
Type 1 Diabetes
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
- Trial name
- SAFEGUARD (NCT07187531)
- Testing
- High Dose SAB-142, Low Dose SAB-142
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 159 people
- Sponsor
- SAb Biotherapeutics, Inc.
Multiple Sclerosis
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body.
- Trial name
- EXO-MOBILITY (NCT07252895)
- Testing
- EXOPULSE Suit in Active mode
- Where
- 11 sites in France
- Volunteers
- 77 people
- Sponsor
- Otto Bock France SNC
Multiple Sclerosis (MS) Relapsing Remitting
A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis
This multicenter, randomized, open-label clinical trial aims to evaluate the efficacy and safety of taurine as an adjunctive therapy to standard disease-modifying treatments (DMTs) in patients with multiple sclerosis (MS).
- Trial name
- NCT07263607
- Testing
- DMTs + taurine, DMTs
- Volunteers
- 80 people
- Sponsor
- Sichuan Academy of Medical Sciences
Type 1 Diabetes Mellitus
Islet Cell Transplant for Type 1 Diabetes
City of Hope National Medical Center, located in Duarte, CA, is hosting a clinical study on islet cell transplantation, an experimental procedure being evaluated as a treatment for patients with type 1 diabetes.
- Trial name
- TCD (NCT01909245)
- Testing
- Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
ITP - Immune Thrombocytopenia
TPO-RA Plus Baricitinib vs. TPO-RA for ITP
This is a prospective, randomized, controlled trial. ITP patients who failed prior full-does TPO-RA monotheray for 14 days. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone.
- Trial name
- NCT07669675
- Testing
- Baricitinib, TPO-RA
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.